ライフサイエンスコーパス: PROTAC

1 PROTAC technology employs small molecules that recruit t

2 PROTACs are heterobifunctional molecules consisting of o

3 PROTACs conjugate a target warhead to an E3 ubiquitin li

4 PROTACs have been developed to degrade a variety of canc

5 PROTACs recruit the E3 ligase to the POI and cause proxi

6 Among the 27 PROTACs synthesized and tested, PROTAC 17 was found to b

7 a study on the metabolism of a series of 40 PROTACs in cryopreserved human hepatocytes at multiple t

8 Based on data for a set of 691 PROTACs, and two project examples, we confirm a sweet sp

9 A PROTAC degrader achieves targeted protein degradation (T

10 er cells supported the discovery of ACBI4, a PROTAC which forms a highly stable and cooperative terna

11 igase should be varied to rapidly generate a PROTAC with the desired degradation profile.

12 vestigation established that MG-277 is not a PROTAC MDM2 degrader but instead works as a molecular gl

13 the first time, we report the formation of a PROTAC by Cu(I)-catalyzed cycloaddition of a thalidomide

14 This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhe

15 KL ligand leading to the identification of a PROTAC molecule that effectively degraded MLKL and compl

16 opment, we discovered that the capacity of a PROTAC to induce degradation involves more than just tar

17 essor p53, we examined the ability of such a PROTAC to decrease cancer cell viability.

18 etation, and both enzymes resulted in active PROTAC metabolism.

19 mine the latest findings from ongoing active PROTAC clinical trials.

20 ding modeling with molecular dynamics to aid PROTAC optimization.

21 is approach is potentially applicable to all PROTACs that recruit these commonly employed E3 ligases.

22 Allosteric PROTACs, noncompetitive molecular glues, and bitopic lig

23 dalities beyond molecular glue degraders and PROTACs.

24 ication of high-affinity ligands to serve as PROTAC starting points remains challenging.

25 ecules that bring proteins together, such as PROTAC degraders.

26 substrates using bivalent compounds known as PROTACs (for 'proteolysis-targeting chimeras').

27 ic proteins by degrader technologies such as PROTACs (proteolysis-targeting chimeras) provides promis

28 ounds outside of the rule-of-5 space such as PROTACs.

29 present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic

30 A nanofibril-based PROTAC strategy to form a polynary (E3)(m) : PROTAC : (P

31 Because a nutlin-based PROTAC should both knockdown its target protein and upre

32 ize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of

33 molecule ligands, there are few nutlin-based PROTAC.

34 In HeLa cells, our SirReal-based PROTAC induced isotype-selective Sirt2 degradation that

35 Thus, our SirReal-based PROTAC is the first example of a probe that is able to c

36 es, en-par or enhanced compared to benchmark PROTACs CM11, 14a, and MZ1.

37 Biological PROTACs (bioPROTACs), which are engineered fusion protei

38 cribe a class of molecules termed biological PROTACs (bioPROTACs)-engineered intracellular proteins c

39 Compared to bivalent PROTACs, SIM1 showed more sustained and higher degradati

40 nce to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackl

41 Bridged PROTAC is a novel protein complex degrader strategy that

42 Altogether, the bridged PROTAC strategy could provide a generalizable platform f

43 Applying this bridged PROTAC strategy, we discovered MS28, the first-in-class

44 nd develop RC-1 as a reversible covalent BTK PROTAC with a high target occupancy as its corresponding

45 A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resi

46 n cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an

47 llular and mechanistic data qualifies bumped PROTAC AGB1 as a potent, fast, and selective degrader of

48 argeted for posttranslational degradation by PROTAC has grown steadily, the number of E3 ligases succ

49 on of the proteasome-mediated degradation by PROTAC requires the formation of a ternary (three-compon

50 me the bioavailability issues encountered by PROTAC payloads.

51 toire of E3 ligases that can be recruited by PROTAC.

52 egradation of the target protein promoted by PROTACs.

53 Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radi

54 Proteolysis-targeting chimaera (PROTAC) technology is an emerging approach for achieving

55 rms such as proteolysis-targeting chimaeras (PROTACs)(1,2) and others (for example, dTAGs(3), Trim-Aw

56 inhibition, proteolysis targeting chimaeras (PROTACs), use of cysteine reactive inhibitors, targeting

57 ics, and novel proteolysis-targeted chimera (PROTAC) technology that have deepened our understanding

58 elopment of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features

59 ased upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation.

60 ased upon the proteolysis targeting chimera (PROTAC) concept.

61 ased upon the proteolysis-targeting chimera (PROTAC) concept.

62 based on the proteolysis targeting chimera (PROTAC) concept.

63 sing both the proteolysis targeting chimera (PROTAC) dBET6 and the AID system, we found that dBET6 tr

64 his approach, proteolysis targeting chimera (PROTAC) degrader antibody conjugates (DACs) provide a un

65 mall-molecule proteolysis-targeting chimera (PROTAC) degraders selective for TRKA over TRKB and TRKC.

66 nversion into proteolysis-targeting chimera (PROTAC) degraders.

67 fforts in the proteolysis targeting chimera (PROTAC) field mostly focus on choosing an appropriate E3

68 MCL1 using a proteolysis targeting chimera (PROTAC) methodology leading to successful degradation.

69 hat combine a proteolysis targeting chimera (PROTAC) payload with a monoclonal antibody via some type

70 Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to ind

71 By using a proteolysis-targeting chimera (PROTAC) strategy that couples an allosteric, reversible

72 Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative the

73 rt the use of proteolysis-targeting chimera (PROTAC) technology to reduce the platelet toxicity of na

74 ader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved e

75 d a series of proteolysis-targeting chimera (PROTAC) that allosterically target BCR-ABL1 protein and

76 ified a novel proteolysis targeting chimera (PROTAC), ARV-825 (ARV), that efficiently degrades bromod

77 -molecule BET proteolysis-targeting chimera (PROTAC), ARV-825, resulted in marked downregulation of s

78 6, a BCL-X(L) proteolysis-targeting chimera (PROTAC), that targets BCL-X(L) to the Von Hippel-Lindau

79 of-of-concept proteolysis-targeting chimera (PROTAC), which efficiently degrades histone deacetylases

80 ns, including proteolysis targeting chimera (PROTAC)-like molecules.

81 nhibition, or proteolysis targeting chimera (PROTAC)-mediated degradation of HPK1 improves the effica

82 knockdown or proteolysis-targeting chimera (PROTAC)-mediated degradation reduced liver TG content in

83 nhibition and proteolysis-targeting chimera (PROTAC)-mediated TRAP1 degradation effectively attenuate

84 based on the proteolysis targeting chimeras (PROTAC) concept.

85 d Rule of 5" Proteolysis Targeting Chimeras (PROTAC) degraders are underdeveloped.

86 des and even PROteolysis TArgeting Chimeras (PROTACs) and proteins.

87 Proteolysis-targeting chimeras (PROTACs) and related molecules that induce targeted prot

88 Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 l

89 Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target pr

90 PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit

91 bifunctional proteolysis targeting chimeras (PROTACs) containing a VHL ligand can hijack the E3 ligas

92 Bivalent proteolysis-targeting chimeras (PROTACs) drive protein degradation by simultaneously bin

93 ed to create proteolysis targeting chimeras (PROTACs) for orthogonal assays of effects of LMO2 degrad

94 gradation by proteolysis targeting chimeras (PROTACs) has gained tremendous momentum for its promise

95 Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic modalities, i

96 PROteolysis-TArgeting Chimeras (PROTACs) have been developed for targeting specific prot

97 (L) specific proteolysis-targeting chimeras (PROTACs) have been developed to circumvent the on-target

98 lecule-based proteolysis-targeting chimeras (PROTACs) have demonstrated that this technology can effe

99 Among them, proteolysis targeting chimeras (PROTACs) have gained great attention in the past decade.

100 e machinery, proteolysis targeting chimeras (PROTACs) have recently been used to target these oncogen

101 ability with Proteolysis Targeting Chimeras (PROTACs) is a key challenge.

102 he design of proteolysis-targeting chimeras (PROTACs) is a powerful small-molecule approach for induc

103 velopment of proteolysis targeting chimeras (PROTACs) is the empirical nature of linker length struct

104 Developing proteolysis-targeting chimeras (PROTACs) is well recognized through target protein degra

105 ches such as proteolysis targeting chimeras (PROTACs) offer new ways to address disease through tackl

106 ) recruiting proteolysis targeting chimeras (PROTACs) or adamantyl-based hydrophobic tags (HyTs).

107 bifunctional PROteolysis TArgeting Chimeras (PROTACs) represent a new emerging class of small molecul

108 Proteolysis targeting chimeras (PROTACs) represent an exciting inhibitory modality with

109 strategies, proteolysis-targeting chimeras (PROTACs) stand out as a significant breakthrough in smal

110 4/6-targeted proteolysis-targeting chimeras (PROTACs) that inhibit CDK6 enzymatic activity in vitro,

111 -situ formed proteolysis-targeting chimeras (PROTACs) to degrade intracellular TYR protein to decreas

112 Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are important for tumo

113 A set of 12 proteolysis targeting chimeras (PROTACs) was synthesized using a solid-phase supported p

114 BRD4) using "Proteolysis Targeting Chimeras (PROTACs)" could be a promising approach.

115 lso known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a

116 specifically proteolysis targeting chimeras (PROTACs), have become a key modality in the protein degr

117 igases as in proteolysis-targeting chimeras (PROTACs), have emerged.

118 l as certain proteolysis targeting chimeras (PROTACs), in development for a range of diseases.

119 ugs, such as proteolysis targeting chimeras (PROTACs), into their bioactive conformation can signific

120 d CRBN-based proteolysis-targeting chimeras (PROTACs), many questions apart from clinical efficacy re

121 ches such as proteolysis-targeting chimeras (PROTACs), molecular glues, and antibody-based degraders

122 l element of proteolysis targeting chimeras (PROTACs), the choice of E3 ubiquitin ligase significantl

123 ing field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concen

124 Finally, we compare PROTAC-mediated protein-level modulation with other tech

125 As a consequence, PROTAC-specific quality criteria should be defined by th

126 The most potent reversible covalent PROTAC, RC-3, exhibited enhanced selectivity toward BTK

127 the degradation by our irreversible covalent PROTACs is driven by reversible binding prior to covalen

128 red to noncovalent and irreversible covalent PROTACs.

129 may pave the way for the design of covalent PROTACs for a wide variety of challenging targets.

130 ond formation, while the reversible covalent PROTACs drive degradation primarily by covalent engageme

131 Reversible covalent PROTACs potentially offer the best of both worlds.

132 reversible covalent, and reversible covalent PROTACs, with <10 nM DC(50)'s and >85% degradation.

133 s, change of mechanism of action (covalents, PROTACs), increases in blood-brain barrier permeability

134 Almost all current PROTACs under clinical studies use the E3 ligase cereblo

135 Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-boun

136 the preparation of cereblon-based degraders (PROTACs, CELMoDs) can be assessed in a single step from

137 Bispecific degraders (PROTACs) of ERa are expected to be advantageous over cur

138 A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by

139 Treatment with the CDK6-degrading PROTAC YX-2-107 markedly suppressed leukemia burden in m

140 somal formulation of EGFR and BRD4-degrading PROTACs (EPRO and BPRO) was prepared and characetrized.

141 the preparation of potential BRD4-degrading PROTACs, resulting in the discovery of a set of degrader

142 Developing PROTACs to redirect the ubiquitination activity of E3 li

143 ited for the synthesis of novel VHL-directed PROTACs with an improved metabolic stability in in vitro

144 croenvironment(5), we developed two distinct PROTAC (proteolysis-targeting chimera) degraders of STAT

145 Cooperative E3-PROTAC-POI complexes have potential to achieve neo-subst

146 the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 (32).

147 ial in the design of permeable and effective PROTACs.

148 The generation of effective PROTACs depends on the nature of the protein/ligase liga

149 ation as an advantageous strategy to enhance PROTAC degradation potency and selectivity between homol

150 ove other PROTACs, opening a path to enhance PROTAC efficacy.

151 ocks and identified the limits of estimating PROTAC solubility from the synthetic components.

152 EZH2 PROTACs induce degradation of both EZH2 and FOXM1, leadi

153 ctural modifications can convert a bona fide PROTAC degrader into a molecular glue compound, which ha

154 , chemical and bioinformatics approaches for PROTAC design, and safety concerns with a special focus

155 eview can serve as a chemistry blueprint for PROTAC researchers during their future ventures into the

156 that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination.

157 the compounds; thus, as a starting point for PROTAC development, both the target ligand and the recru

158 can support TPD, revealing the potential for PROTAC-type development.

159 r BRD7/9 knockdown and provide a roadmap for PROTAC development against seemingly incompatible target

160 results identify DYRKs as viable targets for PROTAC-mediated degradation and qualify DYR684 as a usef

161 E3 ligases that could expand the toolbox for PROTAC discovery.

162 Furthermore, we provide a workflow for PROTAC development and use and discuss the benefits and

163 egrader, a different mechanism-of-action for PROTACs.

164 els generated by large data collections, for PROTACs the knowledge is still limited and heterogeneous

165 lecules but provided dissimilar outcomes for PROTACs.

166 Distinct from PROTACs, these drug-like small molecules insert into a n

167 rticles, the degradation of POI by pre-fused PROTACs was dramatically increased and accelerated compa

168 sion of PROTACs with E3Ps (called "pre-fused PROTACs") before administration could transform the orig

169 ways and new VHL ligands for next-generation PROTACs.

170 Current GPCR PROTACs show the feasibility of using PROTACs to degrade

171 degradation mechanism for some of these GPCR PROTACs is uncertain.

172 A potent and selective HDAC8 PROTAC Z16 (CZH-726) with low nanomolar DC(50) values in

173 We describe Homo-PROTACs as an approach to dimerize an E3 ligase to trigg

174 We provide proof-of-concept of Homo-PROTACs using diverse molecules composed of two instance

175 Altogether, we develop an hRpn13 PROTAC with 2-fold increased potency by optimizing the l

176 ing the linker and VHL ligand, we identified PROTACs 7, 9, and 22 with submicromolar DC(50) values fo

177 nd X-ray cocrystal structures, we identified PROTACs that exhibit high positive cooperativity in form

178 Advances in PROTAC technology facilitated recent development of the

179 A key example is PROTAC 40, modified with a dibasic piperazine, which exh

180 bility of PROTACs to form the ternary ligase-PROTAC-target protein complex and a MSD assay to measure

181 PROTAC strategy to form a polynary (E3)(m) : PROTAC : (POI)(n) complex has not been reported in the T

182 rt the design and synthesis of a macrocyclic PROTAC by adding a cyclizing linker to the BET degrader

183 IMiD-based MDM2 PROTAC 8, which potently reduces MDM2 protein levels thr

184 al modifications of MD-222, a bona fide MDM2 PROTAC degrader, converts it into a "molecular glue", as

185 Also, MEGA PROTAC exhibited 75% superior ranks and a reduced cluste

186 Also, MEGA PROTAC outperforms BOTCP by achieving a twofold improvem

187 Finally, MEGA PROTAC was tested on 22 cases to compare with the state-

188 ses as to which potential drug targets might PROTAC-mediated protein degradation be most applicable.

189 Compared to small-molecule PROTACs, bioPROTACs have higher success rates and are su

190 Moreover, PROTAC-mediated protein degradation offers a general str

191 e of PROTACs for clinical applications, most PROTACs do not make it beyond the preclinical stage of d

192 bine two modalities to yield multifunctional PROTACs with an expanded profile?

193 imary human CD4+ T cells compared to the non-PROTAC parental inhibitor, at limiting inhibitor concent

194 the field rapidly progresses and various non-PROTAC TPD drug candidates emerge, this review explores

195 Although numerous PROTACs have entered clinical trials, their development

196 synthesis, and evaluation of a new class of PROTAC BET degraders.

197 This work culminated with the discovery of PROTAC 23, which we demonstrated to be a potent and sele

198 o not fully assess the off-target effects of PROTAC and are not applicable to RNAi.

199 g the chemical effort in the early stages of PROTAC development.

200 The synthesis of PROTAC compounds that mediate the degradation of c-ABL a

201 be successfully prepared using a variety of PROTAC payloads which employ diverse E3 ligases to degra

202 y assay was used to determine the ability of PROTACs to form the ternary ligase-PROTAC-target protein

203 gical evaluation, and mechanism of action of PROTACs, the characterization of the pharmacokinetic pro

204 ted experimental data with 3D description of PROTACs' structures.

205 physicochemical profiles aided the design of PROTACs, which are known for breaking the rules of estab

206 llular accumulation and target engagement of PROTACs and develop RC-1 as a reversible covalent BTK PR

207 he scientific and preclinical foundations of PROTACs and presents them within common clinical context

208 Herein, we demonstrate that pre-fusion of PROTACs with E3Ps (called "pre-fused PROTACs") before ad

209 e therapeutic space with the introduction of PROTACs into clinical trials for cancer patients.

210 Our results indicated that the metabolism of PROTACs could not be predicted from that of their consti

211 Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can b

212 binding will negate the catalytic nature of PROTACs.

213 Finally, for three pairs of PROTACs we measured the solubility, lipophilicity, and p

214 However, the cell permeability of PROTACs is limited by their high molecular weight and to

215 his review, we will discuss the potential of PROTACs to become anticancer therapeutics, chemical and

216 ally, in silico models for the prediction of PROTACs' kinetic solubility and LogD(7.4) were proposed

217 ping cancer biomarker activating prodrugs of PROTACs.

218 ick chemistry" approach for the synthesis of PROTACs.

219 will transform the synthesis and testing of PROTACs.

220 Despite recent efforts to promote the use of PROTACs for clinical applications, most PROTACs do not m

221 wever, due to the large molecular weights of PROTACs, their cellular uptake remains an issue.

222 cterization of this series, the most optimal PROTAC 23 was identified in primary human and murine cel

223 mically TArgeting Chimeras (PHOTACs) or opto-PROTAC, which is light-induced control of protein degrad

224 s (e.g. antisense oligonucleotides, siRNA or PROTAC), feasibility (availability of resources such as

225 the development of intracellularly oriented PROTACs.

226 administration could transform the original PROTAC system to two-component system.

227 ld improved potency compared to the original PROTAC.

228 t strategy is generalizable to improve other PROTACs, opening a path to enhance PROTAC efficacy.

229 Lastly, we explore the p38delta:PROTAC:VHL complex to explain the different selectivity

230 argeted degradation approaches, particularly PROTACs, BacPROTACs, homo-BacPROTACs, AUTACs, RIBOTACs,

231 report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplifi

232 e and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36.

233 Many potent PROTACs with specificity for dissimilar targets have bee

234 or does not necessarily generate more potent PROTACs and underscores the key roles played by the conj

235 2 employs this UCE for geometrically precise PROTAC-dependent ubiquitylation of a neo-substrate and f

236 ing an ubiquitin ligase to a target protein, PROTACs promote ubiquitination and proteasomal degradati

237 he selection of in silico tools for rational PROTAC development.

238 predict ternary complexes, guiding rational PROTAC design, they have suffered from limited predictiv

239 row single crystals of a cereblon-recruiting PROTAC "AZ1" resulting in structures of an anhydrous for

240 zation of glutarimides, most CRBN-recruiting PROTACs are synthesized as a mixture of racemates or dia

241 biological evaluation of L3MBTL3-recruiting PROTACs and demonstrate nuclear-specific degradation of

242 odeling with molecular dynamics for refining PROTACs.

243 Based upon our previously reported PROTAC MDM2 degraders, we have designed and synthesized

244 ors targeting each domain are available, sEH-PROTACs offer the unique ability to simultaneously block

245 hat treatment of Ph+ ALL with CDK6-selective PROTACs would spare a high proportion of normal hematopo

246 miscuous Bcl-2 family ligands into selective PROTACs.

247 Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (

248 otential to develop tumor-specific/selective PROTACs.

249 the development of tumor-specific/selective PROTACs.

250 eased and accelerated compared with standard PROTACs.

251 A successful PROTAC induces the formation of a ternary complex, leadi

252 ring, and the design elements for successful PROTAC-based drugs are currently being elucidated.

253 lastic lymphoma kinase oncoprotein-targeting PROTACs with enhanced potency and minimal off-target deg

254 Among the 27 PROTACs synthesized and tested, PROTAC 17 was found to be the most potent, degrading LZK

255 Collectively, our results suggest that TF-PROTACs provide a generalizable platform to achieve sele

256 We conclude that PROTAC 23 constitutes an excellent in vitro tool with wh

257 er membrane proteins, there is evidence that PROTACs or other TPD methods could be applied to the GPC

258 nally, conformational analysis revealed that PROTACs can adopt three distinct conformations; however,

259 Although the PROTAC system has not been widely applied to GPCRs and o

260 Coupling the PROTAC-CID platform with genetic circuits, we achieve di

261 We describe the PROTAC technology and its application to drug discovery

262 hese opportunities and decisively enrich the PROTAC toolbox.

263 y (three-component) complex, composed of the PROTAC, the POIs, and E3-ligases related proteins (E3Ps)

264 rotein and the E3 ligase, and optimizing the PROTAC linker.

265 AbTACs represent a new archetype within the PROTAC field to target cell-surface proteins with fully

266 The PROTACs showed enhanced inhibition of B cell activation

267 ngth resulted in playing a major role in the PROTACs' liability.

268 To date, most of the PROTACs developed have utilized ligands to recruit E3 li

269 ability was correlated to the ability of the PROTACs to adopt folded conformations that have a low so

270 methods revealed that the propensity of the PROTACs to adopt folded conformations with a low solvent

271 targeted small-molecule inhibitor therapies, PROTACs can eliminate critical but conventionally "undru

272 These PROTACs can cause on-target toxicities if the POIs are n

273 ereblon ubiquitination pathway, making these PROTACs a first step toward a new class of antiapoptotic

274 By leveraging the innate ability of these PROTACs to degrade MLKL in a dose-dependent manner, the

275 the different selectivity profiles of these PROTACs.

276 Despite featuring identical warheads in this PROTAC series, the linkers were found to affect the resi

277 By using this PROTAC series with slight chemical modifications in the

278 Altogether, TMP PROTACs are a robust approach for selective and reversib

279 erstanding how structural features relate to PROTAC function remains challenging due to the dynamic n

280 enge in clinical oncology, and resistance to PROTACs has been reported in several cancer cell models.

281 Despite this progress, topical PROTACs face some challenges, such as optimizing the sta

282 Triazolodiazepine PROTACs exhibited positive cooperativities of ternary co

283 the development of macrocyclic and trivalent PROTACs.

284 e reported success in the development of two PROTACs (C3 and C5) that potently and selectively induce

285 ct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degrada

286 se findings demonstrate the potential to use PROTAC technology to reduce on-target drug toxicities an

287 t GPCR PROTACs show the feasibility of using PROTACs to degrade GPCRs; however, the degradation mecha

288 e p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4

289 to drug discovery and provide examples where PROTACs have enabled novel biological insights.

290 By combining AI-driven discovery with PROTAC-based target mapping and super-enhancer-centric m

291 malignancies that can be best targeted with PROTAC approach will be briefly discussed.

292 A challenge associated with PROTACs is the time and resource-intensive optimization;

293 r the bioavailability issues associated with PROTACs.

294 cuss the benefits and issues associated with PROTACs.

295 proof of principle" that targeting CDK6 with PROTACs that inhibit its enzymatic activity and promote

296 bispecific nanomolar degraders of ERa, with PROTACs 18 and 21 inhibiting ER+ MCF7 tumor growth in a

297 ting the degradation mechanism of GPCRs with PROTACs are necessary.

298 by converting it into PZ15227 (PZ), a Bcl-xl PROTAC, which targets Bcl-xl to the cereblon (CRBN) E3 l

299 With further improvement, Bcl-xl PROTACs have the potential to become safer and more pote

300 As such, Z-PROTAC likely elicits a positive immunological response,